– Harnessing the convergence of exponential advances in AI, genome sequencing and DNA synthesis technologies, Dyno’s approach to enabling safe and highly efficient in vivo ...

– The work will help advance design capabilities for gene therapies and other sequence-based medicines with potential for transformative patient impact – The collaboration will ...

WATERTOWN, Mass., April 23, 2024 – Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineer AAV capsids that expand the potential ...

– 80x improvement vs. AAV2 in delivery to the retina seen in non-human primate (NHP) – – Head-to-head against other retina-IVT capsids, Dyno eCap 1 ...

WATERTOWN, Mass., October 11, 2023 – Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineering AAV capsids that expand the potential ...

– Dyno bCap 1 exhibits 100x improvement versus AAV9 in delivery to the central nervous system (CNS) and 10x detargeting of liver after intravenous (IV) ...

WATERTOWN, Mass., May 2, 2023 – Dyno Therapeutics, Inc., a techbio company pioneering applications of artificial intelligence to engineering AAV capsids that can expand the ...

BOSTON, MA — March 11, 2022— Dyno Therapeutics is pleased to announce it has been recognized on the Forbes list of America’s Best Startup Employers 2022. ...

Presentations describe use of in vivo screening and machine learning to accelerate the analysis, design, and validation of improved AAV vectors.

Dyno is making AAV gene therapies more effective, safer, more manufacturable and applicable to more diseases, and will expand capacity to meet partnership demand Cambridge, ...

Company will deliver three oral abstracts and host an Industry Symposium Cambridge, MA – April 27, 2021 – Dyno Therapeutics, a biotechnology company applying artificial ...

Scientific leaders bring deep expertise in machine learning and AAV gene therapy Cambridge, MA – April 26, 2021 – Dyno Therapeutics, a biotech company applying ...

Cambridge, MA – February 11, 2020 – Dyno Therapeutics, a biotech company applying artificial intelligence (AI) to gene therapy, today announced a publication in Nature ...

Collaboration combines Dyno’s AI-powered AAV vector capabilities with Roche and Spark Therapeutics’ leading-edge gene therapy capabilities Dyno is eligible to receive milestone payments that may ...

Dyno Therapeutics has been named Startup of the Year by Xconomy, an award that recognizes the most innovative new company with a focus on those ...